Top therapeutic areas

Cancer/Oncology assets continued to dominate accounting for 40% of all biopharma products listed in our database this year. 2400+ partnering-ready assets.

And we saw growth in assets for endocrine and metabolic diseases, blood/immune disorders, and the genitourinary system.

Emerging interest

While antibody and small molecule/NCE assets remain the most common molecule types, there has been an explosion of new microbial assets with 56% growth.

Med tech sector

Increased activity in Software and "Other" categories indicates growing interest in digital and novel technologies.

Investment stages

There was significant growth in early-stage investment opportunities on offer

• Angel (46% increase)
• Seed (31% increase)
• Series A (22% increase)

With late-stage and post-IPO investment opportunities remaining stable.

How does this align with what investors were looking for? The number of investors seeking Angel opportunities was more than double the number of companies offering at this stage. A similar mismatch can be seen at Series C with 60% more investment companies seeking compared to biopharma companies offering.

Who was attending partnering conferences in 2024?

Investor interest in events increased with participation of investment companies increasing by 8%. Attendance by other sectors remained stable.

26% of companies attending our events were based in the United States, and we saw growth in attendance from companies from Spain, Netherlands, and Belgium this year.

What did this look like for us at partneringONE?

• 26 events were powered by partneringONE
• 7,000+ partnering-ready assets and technologies
• 27,000+ licensing and investment professionals are now part of our partneringONE plus network
• 83,000+ one-to-one meetings were arranged